Stage 3 kidney cancer — what it means and how it is treated

Stage 3 kidney cancer is locally advanced disease that has not spread to distant organs. It covers two situations. In the first, the tumour has grown beyond the kidney itself into the fat around it, into the collecting system, or into the renal vein or the vena cava, while staying inside the tough envelope of tissue called Gerota's fascia. In the second, the tumour may still be confined to the kidney but cancer cells have been found in nearby lymph nodes. Either way the scans show no deposits in the lungs, bones, liver or brain. That is the dividing line that matters most: stage 3 is treated with the intention of clearing the disease, not simply of controlling it.

It is treated with curative intent, which means the aim of the plan is to remove all of the cancer rather than to hold it steady. Most people with stage 3 kidney cancer have the affected kidney removed, and for many of them nothing further is needed beyond a follow-up schedule. No oncologist can promise an outcome, and stage 3 does carry a higher chance of the cancer returning than stage 1 or stage 2, which is why the years after surgery matter as much as the operation itself. What helps most is a complete removal, an honest reading of the pathology report afterwards, and follow-up scans that are actually kept.

The difference is distance. Stage 3 means the cancer has grown outside the kidney or reached nearby lymph nodes, but has stayed in the local area, inside Gerota's fascia and with nothing seen elsewhere in the body. Stage 4 means either that the tumour has broken through Gerota's fascia or involved the adrenal gland on the same side, or that cancer has been found in a distant organ such as the lung, bone, liver or brain. The difference changes the shape of treatment. Stage 3 is led by removing the tumour, while stage 4 is usually led by systemic therapy under a medical oncologist, with surgery used selectively.

Surgery comes first for almost everyone. The standard operation removes the whole affected kidney along with the fat around it, and any involved lymph nodes are taken at the same time. Where the tumour has grown into the renal vein or the vena cava, the operation is larger and needs a team used to doing it. At CION that surgery is coordinated for you with specialist urology and uro-oncology partners, where it may also be billed. What follows is decided afterwards from the pathology report: some people move straight to a surveillance schedule, while those at higher risk of recurrence are offered adjuvant immunotherapy, delivered in-house by our medical oncology team along NCCN lines.

It means a column of tumour has extended out of the kidney along the vein that drains it, and sometimes further, into the vena cava. This is called a tumour thrombus. It sounds alarming and it does make the operation bigger, but it is not the same as the cancer having spread to another organ, because the tumour is still travelling inside a vessel rather than seeding elsewhere. The scan describes how far it reaches, from the renal vein alone up to the part of the vena cava above the diaphragm, and that level decides how the surgery is planned and which surgical and anaesthetic teams are involved.

Not everyone does. Once the kidney has been removed, the pathology report is read for the features that predict recurrence: how far the tumour had grown, whether lymph nodes were involved, the grade, and whether sarcomatoid change was present. Where that risk is judged high enough, NCCN guidance supports discussing adjuvant treatment with a checkpoint inhibitor of the PD-1 class, given for a defined period after surgery. Where the risk is lower, surveillance alone is usually the recommendation, because treatment carries its own side effects and should not be given without a reason. Our page on adjuvant immunotherapy after kidney surgery goes through how that decision is made.